ArticleCureus2025
Synchronous Occurrence of Acute Myeloid Leukemia and Multiple Myeloma: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) and acute myeloid leukemia (AML) are malignant clonal disorders with divergent lineages. It is extremely uncommon for both conditions to be diagnosed simultaneously in a patient. This case report examines the uncommon occurrence of AML alongside MM in a 60-year-old male patient. The diagnosis of AML was based on the World Health Organization benchmark, and the patient was categorized as having AML with myelodysplastic defining molecular changes. The patient completed the first cycle of induction chemotherapy with daunorubicin, cytarabine, and gemtuzumab ozogamicin but had a poor response, indicating refractory disease. A bone marrow aspiration following treatment revealed 30% blasts and 11% plasma cells. These plasma cells were CD138 positive and were not present at the time of diagnosis. Additionally, M-protein was detected in the blood. Intermediate chemotherapy with venetoclax and azacitidine was considered, as the patient was not fit for the combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin. Furthermore, the myeloma was not treated as he was not fit for any intensive chemotherapy. The patient's disease was refractory despite four cycles of venetoclax and azacitidine, as evident by residual blasts of 32% in the bone marrow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.